CREB3L1: A Key Regulator of Unfolded Protein Response and Bone Development

Comprehensive genomic and functional analysis of the CREB3L1 gene, its role in osteogenesis imperfecta, and implications in cancer biology.

Gene Information Card

Symbol CREB3L1
Full Name cAMP responsive element binding protein 3 like 1
Gene Type protein-coding
Chromosomal Location 11p11.2
NCBI Gene ID 90993 ncbi.nlm.nih.gov/gene/90993
Ensembl ID ENSG00000157613
UniProt ID Q96BA8
OMIM ID 616215
HGNC ID 18856
Aliases OASIS, CREB-H, CREB3, CREB3L1

Description

CREB3L1 (cAMP responsive element binding protein 3 like 1), also known as OASIS, is a transcription factor that belongs to the CREB/ATF family. It is primarily localized to the endoplasmic reticulum (ER) membrane and is activated upon ER stress through regulated intramembrane proteolysis. Once cleaved, its N-terminal domain translocates to the nucleus to regulate genes involved in the unfolded protein response (UPR), bone matrix formation, and cell differentiation. Mutations in CREB3L1 are associated with osteogenesis imperfecta type XVI, and its dysregulation has been implicated in various cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Osteogenesis Imperfecta Type XVI Loss-of-function mutations in CREB3L1 impair the transcription of collagen type I and other bone matrix proteins, leading to brittle bones and skeletal deformities. OMIM #616215; multiple case reports with homozygous or compound heterozygous mutations
Breast Cancer Overexpression of CREB3L1 has been observed in breast cancer cell lines, potentially promoting metastasis through regulation of UPR target genes. COSMIC; literature on CREB3L1 in cancer cell lines
Glioma CREB3L1 expression is altered in glioblastoma, contributing to tumor progression via ER stress signaling. NCBI Gene expression studies

Expression Profile

Tissue Expression
Tissue nTPM level
Bone 12.5 Medium
Salivary gland 8.3 Low
Pancreas 6.1 Low
Liver 4.7 Low
Brain 3.2 Low
Cell Line Expression
Cell Line nTPM Notes
MCF7 (breast cancer) 15.2 High expression
U2OS (osteosarcoma) 10.8 Moderate expression
HepG2 (liver cancer) 7.4 Low expression
SH-SY5Y (neuroblastoma) 5.1 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1042C>T (p.Arg348*) Nonsense <0.01% Loss of function; truncated protein lacking transactivation domain
c.1A>G (p.Met1?) Missense <0.01% Loss of start codon; no protein production
c.832G>A (p.Gly278Arg) Missense <0.01% Likely loss of function; impaired DNA binding
Mutation functional classification

Loss of Function (LOF)

Nonsense and missense mutations in CREB3L1 lead to loss of transcriptional activity, causing osteogenesis imperfecta type XVI.

Gain of Function (GOF)

Not well documented; overexpression in some cancers may confer gain-of-function effects via UPR activation.

Dominant Negative (DN)

No dominant-negative mutations have been reported for CREB3L1.

Pathways

Unfolded Protein Response (UPR) - Reactome R-HSA-381119
ATF6-alpha activates chaperones - Reactome R-HSA-381183
Collagen biosynthesis and modifying enzymes - Reactome R-HSA-1650814

Protein Summary

CREB3L1 is a 519-amino acid protein with an N-terminal basic leucine zipper (bZIP) domain and a C-terminal transmembrane domain that anchors it to the ER membrane. Under ER stress, it is cleaved by site-1 and site-2 proteases, releasing the N-terminal fragment that enters the nucleus to activate UPR target genes such as BiP, CHOP, and collagen type I. The protein plays a critical role in osteoblast differentiation and bone matrix production.

Related Products

Product name Cat.No. Species Gene ID
CREB3L1 Knockout HEK293 Cell Line EDJ-KQ783 Human 90993 Details Get a Quote
CREB3L1 Knockout A-549 Cell Line EDJ-KQ19489 Human 90993 Details Get a Quote
CREB3L1 Knockout HeLa Cell Line EDJ-KQ19490 Human 90993 Details Get a Quote
CREB3L1 Knockout HCT 116 Cell Line EDJ-KQ74704 Human 90993 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: